Angion Biomedica (NASDAQ:ANGN – Get Rating) announced its quarterly earnings results on Monday. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01), MarketWatch Earnings reports. Angion Biomedica had a negative net margin of 108.57% and a negative return on equity of 43.18%.
NASDAQ:ANGN traded down $0.12 on Thursday, reaching $1.10. The stock had a trading volume of 114,399 shares, compared to its average volume of 111,909. Angion Biomedica has a 1-year low of $1.08 and a 1-year high of $16.26. The stock has a fifty day moving average price of $1.78 and a 200-day moving average price of $2.51.
ANGN has been the topic of a number of research analyst reports. HC Wainwright lowered their price objective on shares of Angion Biomedica from $50.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, April 18th. Zacks Investment Research raised shares of Angion Biomedica from a “hold” rating to a “strong-buy” rating and set a $2.50 price objective for the company in a research note on Tuesday, April 5th.
About Angion Biomedica (Get Rating)
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung.
- Get a free copy of the StockNews.com research report on Angion Biomedica (ANGN)
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
Receive News & Ratings for Angion Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Angion Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.